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Control of Allergic Rhinitis and Asthma Test with 1‐week
recall: Validation of paper and electronic version
To the Editor,
Both asthma and allergic rhinitis (AR) are high prevalence diseases that
frequently occur simultaneously.1,2 The Allergic Rhinitis and its Impact
on Asthma initiative (ARIA) recognizes the need for a concomitant eval-
uation and treatment of asthma and AR.1,2 The Control of Allergic
Rhinitis and Asthma Test (CARAT)3-5 measures control of both asthma
and AR with a 4‐week recall period. In a time where the use of mobile
devices has grown, a new modality to monitor patients is at our dis-
posal. An electronic CARAT questionnaire allows clinicians to gain more
insight into the period between visits and therefore could be a conve-
nient and reliable alternative to the use of the current paper version of
the CARAT. The main purpose of this study was to investigate the psy-
chometric properties of the CARAT with 1‐week recall period as paper
version (CARATp1) and as electronic version (CARATe1).
This is a diagnostic study with repeated measurements in four
consecutive weeks. The study population consisted of consecutive
Dutch primary care asthma patients who were referred by their gen-
eral practitioner to the asthma/COPD service.6 Inclusion criteria were
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Variable Value N
Age, mean (SD) 53.2 (14.3) 111
Gender, n (% male) 49 (42.6) 115
Height, mean (SD) 173 (9.8) 115
BMI, mean (SD) 27.7 (5.8) 112
Current/ex‐smokers, n (%) 68 (58.6) 123
Pack years, MED (IQR)a 11 (4.7‐20.0) 62
Allergic rhinitis 52 (51.0) 102
Medication use (total, n) 123
SABA, n (%) 30 (24.4)
LABA, n (%) 63 (51.2)
LAAC, n (%) 12 (9.8)
ICS, n (%) 77 (62.6)
NCS, n (%) 20 (16.3)
Antihistaminic agent, n (%) 12 (9.8)
Other medication, n (%) 11 (8.9)
No medication, n (%) 29 (23.6)
Lung functionb
FEV1, mean (SD)
c 93.7 (15.5) 110
FVC, mean (SD)c 105.4 (16.2) 110
FEV1/FVC, mean (SD) 74.0 (8.6) 111
ARIA classification (total, n) 52
Intermitting—mild, n (%) 11 (21.2)
Intermitting—moderate/severe, n (%) 1 (1.9)
Persistent—mild, n (%) 25 (48.1)
Persistent—moderate/severe, n (%) 15 (28.8)
VAS
Airway symptoms, MED (IQR)a 20 (10‐50) 116
Upper airway symptoms, MED (IQR)a 20 (0‐50) 115
Lower airway symptoms, MED (IQR)a 20 (3.125‐50) 116
GINA classification (total, n) 95
Well‐controlled, n (%) 23 (24.2)
Partly controlled, n (%) 42 (44.2)
Uncontrolled, n (%) 30 (31.6)
ACQ classification (total, n) 111
Well‐controlled, n (%) 60 (54.1)
Partly controlled, n (%) 29 (26.1)
Uncontrolled, n (%) 22 (19.8)
CARATp1
Total score, MED (IQR)a 24 (18‐27) 105
AR domain score, MED (IQR)a 8 (6‐11) 112
Asthma domain score, MED (IQR)a 15 (11.5‐17) 109
ACQ, asthma control questionnaire; AR, allergic rhinitis; ARIA, Allergic Rhinitis and its Impact on
Asthma initiative; CARAT, Control of Allergic Rhinitis and Asthma Test; FEV1, forced expiratory flow in
1 s; FVC, forced vital capacity; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; IQR,
interquartile range; LAAC, long‐acting anticholinergic; LABA, long‐acting beta‐agonist; MED, median;
NCS, nasal corticosteroid; p1, paper version with 1‐wk recall period; SABA, short‐acting beta‐agonist;
SD, standard deviation; VAS, Visual Analogue Scale.
aIQR of pooled data could not be calculated; bPostbronchodilation; cAs percentage of predicted; nonim-
puted data were used for the descriptive statistics.
TABLE 1 Baseline characteristics
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as follows: age 18‐80 years and asthma diagnosis (made by a pulmo-
nologist based on lung function tests including reversibility and self‐
reported questionnaires). Participation was voluntary, all patients
received oral and written information about the study and all
patients signed informed consent (study approved by the local medi-
cal ethics committee (METc 2014/578)).
In the period between January and August 2015, patients com-
pleted the following questionnaires on paper at baseline: CARATp1,
ARIA2 questions, Visual Analogue Scale (VAS)7 on airway symptoms,
ACQ8 and GINA9 questions. For 4 weeks (T1, T2, T3 and T4), the
patients completed the CARATe1 each Monday and the CARATp1
every Tuesday. In the last week, the patients completed also the
original CARAT on paper (CARATp4) and an evaluation form (see
Table S1, Data S1). The CARAT contains ten questions concerning
asthma symptoms (asthma domain) and AR symptoms (AR domain)
in the previous 4 weeks and is administered on paper.3-5 The only
difference between the CARATp4 and the CARATp1 was the shorter
recall period. The CARATe1 is an electronic application for smart
devices developed by AstraZeneca. It shows, after a short instruction
screen, the CARAT questions on ten consecutive screens.
The construct validity was calculated using Spearman correlation
coefficient (ρ). The CARATp1 at baseline was compared with ARIA,
VAS, GINA and ACQ (ρ 0.6‐0.8 was expected).10 The correlation
between CARATp1 and CARATe1 was calculated using Spearman
correlation coefficient (ρ > 0.80 was expected). The internal consis-
tency of CARATp1 and CARATe1 was determined using Cronbach's
alpha (α 0.70‐0.95 was expected).10 The test‐retest reliability of
CARATp1 and CARATe1 was evaluated with the intraclass correla-
tion coefficient (ICC > 0.70 was expected).10 Aforementioned analy-
sis was performed with CARAT total scores, CARAT AR domain
scores and CARAT asthma domain scores at T1, T2, T3 and T4. The
average scores in each week of both CARATp1 and CARATe1 were
calculated. Spearman correlations of both CARATp1 and CARATe1
with CARATp4 were calculated (ρ > 0.80 was expected). Statistical
analysis was performed using SPSS 25 (IBM, Chicago, USA). Missing
data were assumed to be missing at random and replaced using a
multiple imputation procedure (see Data S1).
In this study, 123 patients were included for analyses and 23% of
the AR patients reported intermitting AR (Table 1) (see Data S1). Con-
struct validity of the CARATp1 was shown by correlation coefficients
within the expected range (ρ 0.584‐0.718) with VAS, ACQ, ARIA and
GINA. As expected, the highest correlation coefficients were found (a)
between AR domain of the CARAT and ARIA and VAS upper airway
symptoms; and (b) between the asthma domain of the CARAT and
GINA, ACQ and VAS lower airway symptoms (Table 2).
CARATp1 was highly correlated with CARATe1 (ρ 0.856‐0.923).
Internal consistency of both CARATp1 and CARATe1 was good
(α 0.754‐0.874) as was the test‐retest reliability (ICC 0.722‐0.931).
CARATp1 and CARATe1 correlated well with the CARATp4
(0.880 and 0.833, respectively). The correlation coefficients of the
CARATp4 and the scores in each week of the CARATp1 were 0.680,
0.812, 0.857 and 0.895, respectively. The correlation coefficients of
the CARATp4 and the scores in each week of the CARATe1 were
0.643, 0.720, 0.817 and 0.806, respectively.
The majority of patients (93%) considered the electronic version
to be easy or very easy to complete and only 6% preferred the
paper version (see Figure S1, Data S1).
This study found that the paper and electronic CARAT question-
naires with a 1‐week recall period are valid and reliable, with com-
parable psychometric properties as the original CARAT4p.3,4
CARATp1 and CARATe1 were strongly correlated with the original
CARAT4p. Also, CARATp1 and CARATe1 were closely correlated.
Moreover, the patients participating in this study considered the
CARATe1 to be user‐friendly. The clinical relevance of these find-
ings is that both new versions of the CARAT are suitable question-
naires for clinical practice and clinical research in patients with
asthma and AR in which the control of both diseases is the out-
come of interest.
TABLE 2 Spearman correlation in
absolute figures as estimation of











Correlation 0.602 0.481 0.580 0.555 0.647 0.612
P‐value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
CARATp1 (AR)
Correlation 0.347 0.584 0.241 0.166 0.309 0.603
P‐value <0.001 <0.001 0.007 0.108 0.001 <0.001
CARATp1 (Asthma)
Correlation 0.645 0.257 0.705 0.659 0.718 0.373
P‐value <0.001 0.004 <0.001 <0.001 <0.001 0.006
All bold printed figures were expected to be >0.60.
ACQ, asthma control questionnaire; AR, allergic rhinitis; ARIA, Allergic Rhinitis and its Impact on
Asthma initiative; CARAT, Control of Allergic Rhinitis and Asthma Test; GINA, Global Initiative for
Asthma; p1, paper version with 1‐wk recall period; VAS, Visual Analogue Scale.
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Interestingly, the correlation of the CARATp4 with the scores in
individual weeks of the CARATp1 and the CARATe1 showed
increasing correlation coefficients. In both cases, the correlation with
the CARATp4 tends to rise as the questionnaires with 1‐week recall
are completed closer in time to when the CARATp4 was completed.
This may suggest that recent weeks play a more prominent role in
the assessment of the patient when completing the CARATp4 than
the first weeks in the recall period. One may argue to prefer the
CARAT with 1‐week recall period to minimize recall bias.
The CARATe1 was viewed favourably by most patients in this
study. Only 6% preferred the CARATp1. This may not be surprising con-
sidering the high level of integration in daily life of smart devices. How-
ever, one patient considered the CARATe1 to be very hard to complete
(65‐year‐old woman). Although this is just one case, it shows that the
paper version of the CARAT should not be fully discarded (see Data S1).
Future research should focus on the calculation of the CARAT's
cut points to differentiate between controlled and uncontrolled
asthma and AR. In addition, the effects of implementation of the
CARATe1 on control and management in primary care should be
investigated. This study showed that both new versions of the
CARAT could be used as convenient tools for both patient and clini-
cian to gain more insight into the control of asthma and AR.
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De novo sensitization to Aspergillus fumigatus in adult asthma
over a 10‐year observation period
To the Editor,
Although exposure and sensitization to respiratory allergens are key
in asthma presentation,1 few studies have investigated longitudinal
changes in sensitization profiles to respiratory allergens among indi-
viduals with asthma.2 Recently, exposure and sensitization to fungal
allergens as risk factors for more persistent, severe asthma have
been investigated.3–6 Considering the chronicity of asthma pathogen-
esis, changes in sensitization profiles to respiratory allergens can
occur temporally and influence prognosis. Physicians sometimes
encounter de novo sensitization (DNS) to Aspergillus fumigatus (Af),
accompanied by allergic bronchopulmonary aspergillosis (ABPA)
onset among patients receiving long‐term asthma treatment.7
Despite its long‐term impact on asthma management, risk factors for
DNS to Af in asthma patients are unclear. We investigated longitudi-
nal changes in sensitization profiles to respiratory allergens and
factors associated with DNS to Af in asthma patients.
Asthma patients treated for ≥10 years at the Sagamihara
National Hospital, a large tertiary‐care hospital for allergic diseases in
central Japan, were assessed. Levels of IgE antibodies (Abs) to aller-
gen extracts from five common fungal allergens and to panels of res-
piratory allergen components were measured in sera obtained
≥10 years ago (1991‐2004, baseline) and compared with those in
recently sampled sera (2015, follow-up). Clinical features were com-
pared between asthma patients with or without DNS to Af. Detailed
study design (Figure S1) and methods are shown in the supporting
information. The ethics committee of Sagamihara National Hospital
approved the study protocol (No. 2016‐023), and written informed
consent was obtained.
To assess longitudinal changes in sensitization to respiratory aller-
gens, data and sera from 139 subjects were analyzed (Study 1). IgE levels
and rates of IgE positivity to respiratory allergens were compared
between baseline and follow‐up. Serum IgE and IgG levels to Af extract
and serum IgE levels to allergen extracts of Candida albicans, Trichophy-
ton rubrum, Malassezia spp., and Alternaria alternata were determined
using a commercial ImmunoCAP system (Thermo Fisher Scientific, Upp-
sala, Sweden); IgE levels ≥0.35 kUA/L were considered positive. Serum
levels of IgE specific for native Der f 1 from house dust mites; nCry j 1,
Japanese cedar; recombinant Phl p 1 and p 5, timothy‐grass; rBet v 1,
birch; nAmb a 1, ragweed; nArt v 1, mugwort; rCan f 1, dogs; rFel d 1,
cats; rAlt a 1, Alternaria alternata; rAsp f 1, f 3, and f 6, Af; rCla h 8, Cla-
dosporium herbarum; and rBla g 1, cockroaches were determined using a
commercial ImmunoCAP Solid‐Phase Allergen Chip (ISAC). IgE levels
≥0.3 ISAC standardized units (ISU) were considered positive.
Study 2 involved risk factor analysis for DNS to Af allergen. Nine
organic lung disease patients at baseline and/or follow‐up were
excluded owing to their high susceptibility to Aspergillus infection
(and accompanying IgE sensitization to Af). After excluding 12 addi-
tional patients positive for IgE to Af extract and/or rAsp f 1 at base-
line, clinical characteristics of 118 patients were compared between
those with or without DNS to rAsp f 1.
Table S1 presents the clinical characteristics of the patients at
baseline and follow‐up (Study 1). The median interval of serum sam-
pling between baseline and follow‐up was 19.1 (IQR, 14.9‐21.4) years.
Figure 1 and Tables S2 and S3 show the frequencies of positivity for
and levels of IgE to each respiratory allergen. Frequencies of patients
positive for IgE to Af extract and to rAsp f 1 noticeably increased
(from 8.6% to 31% and from 0.7% to 13%, respectively) from baseline
to follow‐up. Table 1 shows the association between clinical parame-
ters and DNS to rAsp f 1 after adjusting with serum sampling interval
(Study 2). Among 118 patients, 14 displayed DNS to rAsp f 1. Male
sex, decreased pulmonary function (FEV1/FVC ratio <65%), nonatopic
status at baseline, elevated total IgE levels (>417 IU/mL), and med-
ium‐to‐high dose of ICS (≥500 μg/day) at follow‐up were associated
with DNS to rAsp f 1. Among these 14 patients with DNS to rAsp f 1,
two and six patients satisfied the diagnostic criteria for ABPA and
SAFS, respectively (data not shown).
To our knowledge, this is the first study to clearly document lon-
gitudinal changes in respiratory allergen sensitization and identify
factors associated with DNS to Af. Notably, IgE positivity frequen-
cies against Af extract and rAsp f 1 increased considerably. Our find-
ings from component‐based IgE measurements indicate genuine
changes in sensitization profiles to panels of respiratory allergens.8
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